| Style | Citing Format |
|---|---|
| MLA | Najminejad Z, et al.. "Clinical Perspective: Antibody-Drug Conjugates for the Treatment of Her2-Positive Breast Cancer." Molecular Therapy, vol. 31, no. 7, 2023, pp. 1874-1903. |
| APA | Najminejad Z, Dehghani F, Mirzaei Y, Mer AH, Saghi SA, Abdolvahab MH, Bagheri N, Meyfour A, Jafari A, Jahandideh S, Gharibi T, Amirkhani Z, Delam H, Mashatan N, Shahsavarani H, Abdollahpouralitappeh M (2023). Clinical Perspective: Antibody-Drug Conjugates for the Treatment of Her2-Positive Breast Cancer. Molecular Therapy, 31(7), 1874-1903. |
| Chicago | Najminejad Z, Dehghani F, Mirzaei Y, Mer AH, Saghi SA, Abdolvahab MH, Bagheri N, et al.. "Clinical Perspective: Antibody-Drug Conjugates for the Treatment of Her2-Positive Breast Cancer." Molecular Therapy 31, no. 7 (2023): 1874-1903. |
| Harvard | Najminejad Z et al. (2023) 'Clinical Perspective: Antibody-Drug Conjugates for the Treatment of Her2-Positive Breast Cancer', Molecular Therapy, 31(7), pp. 1874-1903. |
| Vancouver | Najminejad Z, Dehghani F, Mirzaei Y, Mer AH, Saghi SA, Abdolvahab MH, et al.. Clinical Perspective: Antibody-Drug Conjugates for the Treatment of Her2-Positive Breast Cancer. Molecular Therapy. 2023;31(7):1874-1903. |
| BibTex | @article{ author = {Najminejad Z and Dehghani F and Mirzaei Y and Mer AH and Saghi SA and Abdolvahab MH and Bagheri N and Meyfour A and Jafari A and Jahandideh S and Gharibi T and Amirkhani Z and Delam H and Mashatan N and Shahsavarani H and Abdollahpouralitappeh M}, title = {Clinical Perspective: Antibody-Drug Conjugates for the Treatment of Her2-Positive Breast Cancer}, journal = {Molecular Therapy}, volume = {31}, number = {7}, pages = {1874-1903}, year = {2023} } |
| RIS | TY - JOUR AU - Najminejad Z AU - Dehghani F AU - Mirzaei Y AU - Mer AH AU - Saghi SA AU - Abdolvahab MH AU - Bagheri N AU - Meyfour A AU - Jafari A AU - Jahandideh S AU - Gharibi T AU - Amirkhani Z AU - Delam H AU - Mashatan N AU - Shahsavarani H AU - Abdollahpouralitappeh M TI - Clinical Perspective: Antibody-Drug Conjugates for the Treatment of Her2-Positive Breast Cancer JO - Molecular Therapy VL - 31 IS - 7 SP - 1874 EP - 1903 PY - 2023 ER - |